Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Chronic myeloid leukemia (CML) is characterized by the Philadelphia chromosome and the BCR::ABL1 fusion gene.
• CML presents in three phases: chronic, accelerated, and blast.
• Tyrosine kinase inhibitor (TKI) therapy is a standard treatment for chronic phase CML.

Purpose of the Study:

• To review NCCN Guidelines for chronic phase CML diagnosis and management.
• To highlight the role of TKI therapy in preventing CML progression.
• To discuss the feasibility of TKI discontinuation in select CML patients.

Main Methods:

• Review of current NCCN Guidelines for CML.
• Analysis of TKI therapy efficacy in chronic phase CML.
• Evaluation of criteria for TKI discontinuation.

Main Results:

• TKI therapy is highly effective in managing chronic phase CML and preventing progression.
• Careful monitoring allows for TKI discontinuation in selected patients.
• NCCN Guidelines provide a framework for CML diagnosis and treatment.

Conclusions:

• Management of chronic phase CML involves TKI therapy aimed at preventing progression.
• TKI discontinuation is a viable option for specific patients.
• Adherence to NCCN Guidelines ensures optimal CML care.